Supplementary Figure S2 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial

Federico Rojo; Clive R. Taylor; Carlos H. Barrios; Laura Torrecillas; Manuel Ruíz-Borrego; Sandra Pérez‐Buira; José Bines; Ángel Guerrero‐Zotano; José Á. García-Sáenz; Roberto Torres; Juan de la Haba-Rodríguez; Francisco Ayala; Henry Gómez; Antonio Llombart‐Cussac; María Rodríguez de la Borbolla; José Manuel Baena-Cañada; Agustí Barnadas; Lourdes Calvo; Jesús Herránz; Raúl Rincón; Rosalía Caballero; Begoña Bermejo; Partha S. Ray; Miguel Martín

doi:10.1158/1078-0432.30029041

Key Points

Patients receiving capecitabine showed improved overall survival compared to those under observation.
The analysis focuses on patients from the GEICAM_CIBOMA trial, emphasizing FOXC1's role in predicting treatment efficacy.
Overall survival rates suggest significant benefits of capecitabine in the context of triple-negative breast cancer therapy.
These findings indicate the potential of FOXC1 as a biomarker for personalized medicine in cancer treatments.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Survival analyses reveal overall survival benefits in patients receiving capecitabine, highlighting FOXC1 as a predictive marker.

Abstract

Survival analyses showing the secondary endpoint of overall survival (OS) for patients randomly assigned to capecitabine or observation in the GEICAM_CIBOMA translational study cohort

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Rojo et al. (2025) studied this question.

synapsesocial.com/papers/68c182609b7b07f3a060f678 https://doi.org/10.1158/1078-0432.30029041

View Full Paper

Ask AI

Bookmark

Share

Supplementary Figure S2 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Supplementary Figure S2 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading